# Rimonci Capital

> Rimonci Capital is a VC fund backing Health Care and Medical Device. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 10
- Last investment: Feb 2025
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/rimonci-capital
- Website: https://www.rimonci.com

Rimonci Capital is a VC fund in Beijing focused on Health Care and Medical Device. A dedicated to China-Israel cross border investment.

## Contacts

5 contacts available for Rimonci Capital. Shizune tracks 2 team members at Rimonci Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/rimonci-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3.6M–$3.6M |
| Series A | $6.6M–$11M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 50% |
| Medical Device | 5 | 50% |
| Eyewear | 2 | 20% |
| Medical | 2 | 20% |
| Laser | 1 | 10% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 50% |
| Seed | 1 | 10% |
| Series B | 1 | 10% |
| Series C | 1 | 10% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 5 | 50% |
| France | 1 | 10% |
| United States | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Richel Liu | Founder and CEO | 6 | https://shizune.co/investors/profile/richel-liu |
| Eddie Wang | COO and Co-Founder | 0 | https://shizune.co/investors/profile/eddie-wang-0a5e |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TECLens | TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M | Series A | Feb 11, 2025 |  |
| Laclarée | Laclarée develops a pair of adaptive eyeglasses for presbyopia. Its patented technology allows the eyeglasses to adapt in real-time to the scene viewed by the wearer. This major innovation will help milllions of people 45+ years, who are not satisfied with current solutions (progressive lenses, multiple pairs, etc...). | $3.6M | Seed | Jan 28, 2025 |  |
| Laclarée | Laclarée develops a pair of adaptive eyeglasses for presbyopia. Its patented technology allows the eyeglasses to adapt in real-time to the scene viewed by the wearer. This major innovation will help milllions of people 45+ years, who are not satisfied with current solutions (progressive lenses, multiple pairs, etc...). | $3.6M | Seed | Jan 28, 2025 |  |
| EyeYon | EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $25M | Series C | Mar 15, 2021 |  |
| EyeControl | EyeControl is a pioneer of medical technology, specializing in innovative communication solutions that address unmet healthcare needs. We implement disruptive AI-technologies that connect people and bridge information barriers, facilitating better medical care and decision-making. Our eye-tracking wearable and smart platforms empowercomprehensive, round-the-clock, bi-directional connectivity between patients with communication difficulties, their families, and medical teams. Using adaptive, ML-based pattern recognition, eye gestures are analyzed and converted to real-time communication and actionable clinical data for patients with various levels of cognition. Established in 2016 by individuals, who share unique personal connections to Locked-in patients, EyeControl is a privately held, rapidly growing startup. Recognized as spearheads of cutting-edge medical innovation, the company is supported by the European Innovation Council, Israel Innovation Authority, investors and advisors representing various sectors.The EyeControl device is FDA listed, CE marked, ISO certified, AMAR registered, and HIPAA compliant; it is federally reimbursed in Israel, the UK, and the US. Clinical trials validating its efficacy in detecting and mitigating Delirium are underway in Israel and the US. |  | Series A | Aug 12, 2020 |  |
| BELKIN Vision | BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $12.3M | Series B | Jul 21, 2020 |  |
| NovaSight | NovaSight brings pediatric vision care into the digital age. Our integrated eye-tracking AI based solutions for accurate vision assessment and efficient treatment are specifically designed for the unique needs and attention span of children.NovaSight’s management and scientific advisory board is comprised of experienced executives, researchersand key opinion leaders in the field of pediatric vision care. | $8M | Series A | Jul 13, 2020 |  |
| 6over6 | 6over6 offers a digital healthcare platform that enables users to perform their own eye vision test. They have reimagined all fundamental optometric tools and fitted them into smartphone, enabling a complete and accurate measurement of the refractive error of the eye, for eyeglasses and contact lens prescription, using software.GlassesOn isregistered as a Class 1 Exempt Medical Device on the FDA Medical Device Listings. However, GlassesOn does not provide medical advice, and does not replace a full eye health exam. | $11M | Series A | Nov 11, 2017 |  |
| BELKIN Vision | BELKIN Vision develops a laser device to assist healthcare professionals in treating glaucoma. It offers non-invasive, non-contact, instantaneous, painless, and automated devices offering laser therapy and is aimed at promoting accessibility to first-line drop-less glaucoma care by allowing any ophthalmologist to treat patients. | $6.6M | Series A | Jun 05, 2017 |  |
| EyeYon | EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema.EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer TechnologyIncubator. | $6.5M |  | Mar 21, 2017 |  |

10 of 10 investments shown.

## Co-investors
- [CR-CP Life Science Fund](https://shizune.co/investors/profile/cr-cp-life-science-fund) — VC Fund, 2 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 2 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 2 deals together
- [Triventures](https://shizune.co/investors/profile/triventures) — VC Fund, 2 deals together
- [UI Investissement](https://shizune.co/investors/profile/ui-gestion) — VC Fund, 2 deals together
- [Benslie Investment Group](https://shizune.co/investors/profile/benslie-international-ltd) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Medical Device Investors in Middle East](https://shizune.co/investors/medical-device-investors-middle-east)
- [Medical Device VC Funds in Middle East](https://shizune.co/investors/medical-device-vc-funds-middle-east)
- [Medical Device Investors in Israel](https://shizune.co/investors/medical-device-investors-israel)
- [Medical Device VC Funds in Israel](https://shizune.co/investors/medical-device-vc-funds-israel)
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)

## FAQ

### What does Rimonci Capital invest in?

Rimonci Capital invests primarily in Health Care, Medical Device and Eyewear startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Rimonci Capital's check size?

Rimonci Capital typically joins rounds of $3.6M–$3.6M at Seed and $6.6M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rimonci Capital participates in.

### How do I contact Rimonci Capital?

Public channels for Rimonci Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Rimonci Capital?

The team at Rimonci Capital includes Richel Liu (Founder and CEO) and Eddie Wang (COO and Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co